Supprelin LA Alternatives Compared
| Supprelin LA | Lupron Depot-PED | Tamoxifen |
|
|---|
| Supprelin LA (histrelin) | Lupron Depot-PED (leuprolide) | Tamoxifen |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Precocious Puberty, Prostate Cancer. Supprelin LA may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Precocious Puberty. Lupron Depot-PED may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Breast Cancer, Breast Cancer - Adjuvant, Breast Cancer - Metastatic, Breast Cancer - Male, Breast Cancer - Palliative, McCune-Albright Syndrome, Precocious Puberty. May also be... View more |
Related suggestions Precocious Puberty
Popular comparisons
|
|||||||||||||||||||||||
| More about Supprelin LA (histrelin) | More about Lupron Depot-PED (leuprolide) | More about Tamoxifen | ||||||||||||||||||||||||
| Generic Status | ||||||||||||||||||||||||||
|
No lower-cost generic available |
||||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Supprelin LA has an average rating of 5.5 out of 10 from a total of 2 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 50% reported a negative effect. |
Lupron Depot-PED has an average rating of 5.6 out of 10 from a total of 25 ratings on Drugs.com. 39% of reviewers reported a positive effect, while 33% reported a negative effect. |
Tamoxifen has an average rating of 5.5 out of 10 from a total of 96 ratings on Drugs.com. 31% of reviewers reported a positive effect, while 29% reported a negative effect. |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Side Effects | ||||||||||||||||||||||||||
|
See also: Supprelin LA side effects in more detail. |
See also: Lupron Depot-PED side effects in more detail. |
Commonly reported side effects include:
See also: tamoxifen side effects in more detail. |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Supprelin LA prices |
View all Lupron Depot-PED prices and generic prices |
View all tamoxifen prices |
||||||||||||||||||||||||
| Dosage Form(s) Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Other histrelin brands include: Vantas | Other leuprolide brands include: Camcevi, Eligard, Fensolvi, Lupron Depot | Soltamox | ||||||||||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
|
N/A |
4.25 hours |
231 hours |
||||||||||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 273 drugs are known to interact with Supprelin LA:
|
A total of 273 drugs are known to interact with Lupron Depot-PED:
|
A total of 397 drugs are known to interact with tamoxifen:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
|
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
N/A |
N/A |
October 27, 2017 |
||||||||||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.